In phase III AUGMENT trial presented by Dr. John Leonard at the 2022 American Society of Hematology (ASH) Annual Meeting, the addition of #lenalidomide to #rituximab maintained an improved progression-free survival (PFS) compared with rituximab alone in patients with relapsed/refractory indolent #non-Hodgkin lymphoma according to 5-year findings.

In this trial, 358 patients with relapsed and/or refractory #follicular or #marginal_zone lymphoma were randomly assigned 1:1 to either the rituximab plus lenalidomide arm or the placebo arm for a total of 12 cycles. In the rituximab plus lenalidomide arm, the median PFS was 27.6 months compared with 14.3 months in the placebo arm (HR = 0.50; P <.0001). The updated results for OS are consistent with the improvement observed in PFS even though, median overall survival (OS) in both the combination and placebo arms was not reached (HR, 0.59; P = .028). Moreover, the 5-year OS rates were 83.2% vs 77.3% for the rituximab plus lenalidomide arm and placebo arms, respectively.

These updated results further support the use of the regimen as a standard of care for patients with relapsed/refractory indolent non-Hodgkin lymphoma